Merck Serono Ventures joins extended seed round for EpiTherapeutics, which has raised DKr51.5m ($9.2m) since launching in October 2008.

EpiTherapeutics, a Denmark-based biopharmaceutical company developing anti-cancer drugs, has received research fees and potential royalties from peer Abbott to work on a new treatment and also added Merck Serono’s corporate venturing unit as its latest member of its investment consortium.

The value of the upfront or royalty payments from Abbott to EpiTherapeutics were undisclosed.

Merck Serono Ventures joined the extended seed round for EpiTherapeutics, which has raised DKr51.5m ($9.2m) since launching in October 2008. Merck Serono Ventures joins Lundbeckfond…